# A Study of Tocilizumab in Comparison to Etanercept in Participants With Rheumatoid Arthritis and Cardiovascular Disease Risk Factors

> **NCT01331837** · PHASE4 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 3080 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DRUG:** Etanercept
- **DRUG:** Tocilizumab

## Key facts

- **NCT ID:** NCT01331837
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-08-02
- **Primary completion:** 2016-03-25
- **Final completion:** 2016-03-25
- **Target enrollment:** 3080 (ACTUAL)
- **Last updated:** 2017-07-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01331837

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01331837, "A Study of Tocilizumab in Comparison to Etanercept in Participants With Rheumatoid Arthritis and Cardiovascular Disease Risk Factors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01331837. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*